Although not labeled as such by the FDA, TMS is considered a third line treatment by many practitioners and health insurance company policies. Earlier referral to TMS is not commonly practiced but may be non-inferior to or superior to medication switches or augmentation. Our field lacked trials that compared different modalities of treatment in parallel with TMS until recently, which is the subject of this webinar.